Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Robert Rose who wrote (844)	3/16/2000 9:46:00 AM
From: Biomaven	Respond to of 52153

What are those warning signals? Skimping on Phase II studies, borderline statistical significance, lack of a sensible dose-response curve, post-hoc analyses of subsets of data, indications that have proven hard in the past (like sepsis, shock and ARDS), pharma partners that have "enabled the company to reacquire its rights", multiple previous failures by the company, sudden talk about backup compounds, unusually slow enrollment in studies, sudden need for more animal studies late in the game, and skepticism by people like Miljenko and Rick who are blessed with a good nose. Of course sometimes you just get blindsided - for example, the deaths in Biogen's Phase II of their CD40 project seemed to come out of the blue and may have killed one of the most promising compounds in all biotechland. Peter